Critical reviews in oncology/hematology最新文献_第8页

The role of radium-223 in the evolving treatment landscape of metastatic castration-resistant prostate cancer: A narrative review 镭-223在转移性去势抵抗性前列腺癌不断发展的治疗前景中的作用：一个叙述性的回顾。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2025-03-08 DOI: 10.1016/j.critrevonc.2025.104678

Álvaro Pinto , Mario Domínguez , Alfonso Gómez-Iturriaga , Alejo Rodriguez-Vida , Juan Antonio Vallejo-Casas , Elena Castro

{"title":"The role of radium-223 in the evolving treatment landscape of metastatic castration-resistant prostate cancer: A narrative review","authors":"Álvaro Pinto , Mario Domínguez , Alfonso Gómez-Iturriaga , Alejo Rodriguez-Vida , Juan Antonio Vallejo-Casas , Elena Castro","doi":"10.1016/j.critrevonc.2025.104678","DOIUrl":"10.1016/j.critrevonc.2025.104678","url":null,"abstract":"<div><div>The treatment of metastatic castration-resistant prostate cancer (mCRPC) has been rapidly evolving over the last two decades. The advent of new androgen receptor pathway inhibitors (ARPIs) such as abiraterone acetate or enzalutamide marks a great advance for treating mCRPC patientd in the pre- and post-docetaxel settings. The subsequent approval of ARPIs in early stages—i.e., metastatic hormone-sensitive (mHSPC) or nonmetastatic CRPC—led to a realignment of subsequent treatment choices upon progression to mCRPC, given the possibility of cross-resistance between ARPIs. Therapies with mechanisms of action different from those of ARPIs are now the focus of new treatment developments. Also, this anomalous situation brings the focus back to well-known treatments currently used later in the treatment sequence. This is the case of radium-223 which, when administered with enzalutamide, has recently been shown to prolong radiographic progression-free survival vs. enzalutamide alone in the first line in asymptomatic or mildly symptomatic patients with no known visceral metastases. In this narrative review, we summarize the treatment landscape for mCRPC, both from a historical and practical point of view, to understand the new potential of radium-223 as a treatment option in this setting.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"210 ","pages":"Article 104678"},"PeriodicalIF":5.5,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143588629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial intelligence and whole slide imaging, a new tool for the microsatellite instability prediction in colorectal cancer: Friend or foe? 人工智能和全切片成像——预测结直肠癌微卫星不稳定性的新工具：是敌是友？

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2025-03-08 DOI: 10.1016/j.critrevonc.2025.104694

Anna Lucia Cannarozzi , Giuseppe Biscaglia , Paola Parente , Tiziana Pia Latiano , Annamaria Gentile , Davide Ciardiello , Luca Massimino , Anna Laura Pia Di Brina , Maria Guerra , Francesca Tavano , Federica Ungaro , Fabrizio Bossa , Francesco Perri , Anna Latiano , Orazio Palmieri

{"title":"Artificial intelligence and whole slide imaging, a new tool for the microsatellite instability prediction in colorectal cancer: Friend or foe?","authors":"Anna Lucia Cannarozzi , Giuseppe Biscaglia , Paola Parente , Tiziana Pia Latiano , Annamaria Gentile , Davide Ciardiello , Luca Massimino , Anna Laura Pia Di Brina , Maria Guerra , Francesca Tavano , Federica Ungaro , Fabrizio Bossa , Francesco Perri , Anna Latiano , Orazio Palmieri","doi":"10.1016/j.critrevonc.2025.104694","DOIUrl":"10.1016/j.critrevonc.2025.104694","url":null,"abstract":"<div><div>Colorectal cancer (CRC) is the third most common and second most deadly cancer worldwide. Despite advances in screening and treatment, CRC is heterogeneous and the response to therapy varies significantly, limiting personalized treatment options. Certain molecular biomarkers, including microsatellite instability (MSI), are critical in planning personalized treatment, although only a subset of patients may benefit. Currently, the primary methods for assessing MSI status include immunohistochemistry (IHC) for DNA mismatch repair proteins (MMRs), polymerase chain reaction (PCR)-based molecular testing, or next-generation sequencing (NGS). However, these techniques have limitations, are expensive and time-consuming, and often result in inter-method inconsistencies. Deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H) are critical predictive biomarkers of response to immune checkpoint inhibitor (ICI) therapy and MSI testing is recommended to identify patients who may benefit. There is a pressing need for a more robust, reliable, and cost-effective approach that accurately assesses MSI status. Recent advances in computational pathology, in particular the development of technologies that digitally scan whole slide images (WSI) at high resolution, as well as new approaches to artificial intelligence (AI) in medicine, are increasingly gaining ground. This review aims to provide an overview of the latest findings on WSI and advances in AI methods for predicting MSI status, summarize their applications in CRC, and discuss their strengths and limitations in daily clinical practice.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"210 ","pages":"Article 104694"},"PeriodicalIF":5.5,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143598151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incorporating radiomic MRI models for presurgical response assessment in patients with early breast cancer undergoing neoadjuvant systemic therapy: Collaborative insights from breast oncologists and radiologists 结合放射MRI模型评估接受新辅助全身治疗的早期乳腺癌患者的术前反应：来自乳腺肿瘤学家和放射学家的合作见解。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2025-03-07 DOI: 10.1016/j.critrevonc.2025.104681

Mariangela Gaudio , Giulia Vatteroni , Rita De Sanctis , Riccardo Gerosa , Chiara Benvenuti , Jacopo Canzian , Flavia Jacobs , Giuseppe Saltalamacchia , Gianpiero Rizzo , Paolo Pedrazzoli , Armando Santoro , Daniela Bernardi , Alberto Zambelli

{"title":"Incorporating radiomic MRI models for presurgical response assessment in patients with early breast cancer undergoing neoadjuvant systemic therapy: Collaborative insights from breast oncologists and radiologists","authors":"Mariangela Gaudio , Giulia Vatteroni , Rita De Sanctis , Riccardo Gerosa , Chiara Benvenuti , Jacopo Canzian , Flavia Jacobs , Giuseppe Saltalamacchia , Gianpiero Rizzo , Paolo Pedrazzoli , Armando Santoro , Daniela Bernardi , Alberto Zambelli","doi":"10.1016/j.critrevonc.2025.104681","DOIUrl":"10.1016/j.critrevonc.2025.104681","url":null,"abstract":"<div><div>The assessment of neoadjuvant treatment’s response is critical for selecting the most suitable therapeutic options for patients with breast cancer to reduce the need for invasive local therapies. Breast magnetic resonance imaging (MRI) is so far one of the most accurate approaches for assessing pathological complete response, although this is limited by the qualitative and subjective nature of radiologists' assessment, often making it insufficient for deciding whether to forgo additional locoregional therapy measures. To increase the accuracy and prediction of radiomic MRI with the aid of machine learning models and deep learning methods, as part of artificial intelligence, have been used to analyse the different subtypes of breast cancer and the specific changes observed before and after therapy. This review discusses recent advancements in radiomic MRI models for presurgical response assessment for patients with early breast cancer receiving preoperative treatments, with a focus on their implications for clinical practice.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"210 ","pages":"Article 104681"},"PeriodicalIF":5.5,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143588579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular oncology of iodine refractory thyroid cancer current therapies and perspective 碘难治性甲状腺癌分子肿瘤学研究现状及展望。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2025-03-03 DOI: 10.1016/j.critrevonc.2025.104679

François Cherifi , Ahmad Awada

引用次数: 0

Advances of artificial intelligence in clinical application and scientific research of neuro-oncology: Current knowledge and future perspectives 人工智能在神经肿瘤临床应用和科学研究中的进展：当前知识和未来展望。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2025-03-01 DOI: 10.1016/j.critrevonc.2025.104682

Yankun Zhan , Yanying Hao , Xiang Wang , Duancheng Guo

{"title":"Advances of artificial intelligence in clinical application and scientific research of neuro-oncology: Current knowledge and future perspectives","authors":"Yankun Zhan , Yanying Hao , Xiang Wang , Duancheng Guo","doi":"10.1016/j.critrevonc.2025.104682","DOIUrl":"10.1016/j.critrevonc.2025.104682","url":null,"abstract":"<div><div>Brain tumors refer to the abnormal growths that occur within the brain’s tissue, comprising both primary neoplasms and metastatic lesions. Timely detection, precise staging, suitable treatment, and standardized management are of significant clinical importance for extending the survival rates of brain tumor patients. Artificial intelligence (AI), a discipline within computer science, is leveraging its robust capacity for information identification and combination to revolutionize traditional paradigms of oncology care, offering substantial potential for precision medicine. This article provides an overview of the current applications of AI in brain tumors, encompassing the primary AI technologies, their working mechanisms and working workflow, the contributions of AI to brain tumor diagnosis and treatment, as well as the role of AI in brain tumor scientific research, particularly in drug innovation and revealing tumor microenvironment. Finally, the paper addresses the existing challenges, potential solutions, and the future application prospects. This review aims to enhance our understanding of the application of AI in brain tumors and provide valuable insights for forthcoming clinical applications and scientific inquiries.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"209 ","pages":"Article 104682"},"PeriodicalIF":5.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143544918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Resistance to PD-1/PD-L1 immune checkpoint blockade in advanced non-small cell lung cancer 晚期非小细胞肺癌对PD-1/PD-L1免疫检查点阻断的耐药性

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2025-02-28 DOI: 10.1016/j.critrevonc.2025.104683

Lijun Li, Haihong Pu, Xiaoxin Zhang, Xiaotian Guo, Guangrui Li, Minghui Zhang

引用次数: 0

Chimeric antigen receptor T cell immunotherapy for gynecological malignancies 嵌合抗原受体T细胞免疫治疗妇科恶性肿瘤。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2025-02-28 DOI: 10.1016/j.critrevonc.2025.104680

Yajuan Gao , Jing He , Jing Wang , Haiou Xu , Lin Ma

{"title":"Chimeric antigen receptor T cell immunotherapy for gynecological malignancies","authors":"Yajuan Gao , Jing He , Jing Wang , Haiou Xu , Lin Ma","doi":"10.1016/j.critrevonc.2025.104680","DOIUrl":"10.1016/j.critrevonc.2025.104680","url":null,"abstract":"<div><div>Gynecologic malignancies pose a serious threat to women's health worldwide. Although immunotherapy has significantly revolutionized cancer treatment strategies, effective therapeutic options for recurrent or advanced gynecologic malignancies are still deficient, posing significant challenges to clinical therapy. Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable efficacy in treating hematologic malignancies, marking a significant change in the oncology treatment paradigm. However, despite the gradual increase in CAR T cell therapy used in treating solid tumors in recent years, its efficacy in treating gynecologic malignancies still needs further validation. This review will thoroughly examine CAR-T cell engineering and its mechanism of action on specific antigens associated with gynecologic malignancies, systematically assess the current application of CAR T cell therapy in gynecologic tumors and the advancements in clinical trials, and discuss the significant challenges and corresponding strategies, thereby offering a scientific foundation and guidance for future research in this area.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"209 ","pages":"Article 104680"},"PeriodicalIF":5.5,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143538257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heterogeneity of the tumor immune cell microenvironment revealed by single-cell sequencing in head and neck cancer 单细胞测序揭示头颈部肿瘤免疫细胞微环境的异质性

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2025-02-27 DOI: 10.1016/j.critrevonc.2025.104677

Chunhong Li , Jia Liao , Bo Chen , Qiang Wang

引用次数: 0

Meta-analysis of clinical trial on the comparative efficacy and safety profiles of immunotherapeutic strategies in cervical cancer 宫颈癌免疫治疗策略的疗效和安全性对比临床试验荟萃分析

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2025-02-27 DOI: 10.1016/j.critrevonc.2025.104673

Navya V.B., Ravindra Kumar

{"title":"Meta-analysis of clinical trial on the comparative efficacy and safety profiles of immunotherapeutic strategies in cervical cancer","authors":"Navya V.B., Ravindra Kumar","doi":"10.1016/j.critrevonc.2025.104673","DOIUrl":"10.1016/j.critrevonc.2025.104673","url":null,"abstract":"<div><div>Over the years, there have been significant advancements in the field of cervical cancer research in developing new treatment approaches. One of the significant breakthroughs in cancer treatment is the emergence of immunotherapy that can be used as a standalone treatment or in combination with other cancer therapies. Immunotherapy has shown promising results in clinical trials and has become a viable strategy for treating cancer and improves the quality of life for cancer patients and overall survival rate. Here in the systematic review we are focusing towards the effectiveness and safety of immunotherapy in cervical cancer or HPV infections CIN with clinical trial data. The data extracted had from those studies were analyzed through certain statistical methods and subgroup analysis for validating and concluding our objective. PubMed and Science direct database were used for searching the studies with applied screening and filtering and 49 main reports were included for the studies. The immunotherapies subdivided to immune checkpoint inhibitors, cellular therapy and Vaccine were separately analysed through meta-analysis for the conclusion. The Pembrolizumab (immune checkpoint inhibitor), T cell therapy and Bivalent (Ecoli expressed) vaccine were analysed to be higher effective. Thus for future exploration on immunotherapy in cervical cancer, it was described in our studies of a combination of Ecoli rec HPV bivalent vaccine followed by Pembrolizumab or T cell therapy thus improving the immune mediated action against the cancer. Apart from that, a hypothetical model of multiepitope production on ecoli for vaccine generation has also been explained.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"209 ","pages":"Article 104673"},"PeriodicalIF":5.5,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143534268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Relationship between purinergic signalling and oxidative stress in prostate cancer: Perspectives for future therapy 前列腺癌中嘌呤能信号传导与氧化应激的关系：未来治疗的观点。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2025-02-25 DOI: 10.1016/j.critrevonc.2025.104675

Rafael Zatti Rossetto , Sarah Franco Vieira De Oliveira Maciel , Andréia Machado Cardoso

{"title":"Relationship between purinergic signalling and oxidative stress in prostate cancer: Perspectives for future therapy","authors":"Rafael Zatti Rossetto , Sarah Franco Vieira De Oliveira Maciel , Andréia Machado Cardoso","doi":"10.1016/j.critrevonc.2025.104675","DOIUrl":"10.1016/j.critrevonc.2025.104675","url":null,"abstract":"<div><div>Prostate cancer (PCa) is a complex and lethal disease in men, influenced by risk factors such as age, heredity, and lifestyle. This article reviews the roles of purinergic signaling and reactive species in PCa progression. The purinergic system involves signaling molecules, such as ATP and adenosine, specific receptors (P1 and P2), and catalytic enzymes (for example, CD39 and CD73), whose alterations contribute to cell proliferation, angiogenesis, and immune evasion. The purinergic receptors P2X7 and P2X4 modulate the prostate tumor microenvironment (TME), impacting hypoxia, apoptosis, and inflammatory pathways. Reactive oxygen species (ROS) and nitrogen species (RNS) also play crucial roles. At elevated levels, they lead to oxidative damage to DNA and mitochondria, promoting genetic instability and uncontrolled cell proliferation. These species interact with the purinergic signaling pathway, with enzymes like CD39 and CD73 playing dual roles: degrading extracellular ATP to generate immunosuppressive adenosine while simultaneously protecting against oxidative damage. This review emphasizes the dynamic interplay between inflammatory and immunosuppressive signals within the TME, mediated by ATP, ROS, and their signaling cascades. This balance determines whether the environment supports tumor progression or regression. Targeting these mechanisms through innovative therapies, including receptor inhibitors and ROS modulation, presents promising avenues for PCa treatment. Understanding the intricate roles of purinergic signaling and reactive species provides valuable insights into potential therapeutic strategies to combat PCa.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"209 ","pages":"Article 104675"},"PeriodicalIF":5.5,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143525594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0